financetom
Business
financetom
/
Business
/
Dentsu Creative India: In advertising, technology is just a tool, it is the idea that resonates with people
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dentsu Creative India: In advertising, technology is just a tool, it is the idea that resonates with people
Jul 9, 2022 6:30 AM

It has been a historic year for India at the Cannes Lions Festival of Creativity with a lot of the credit going to Dentsu Creative Bengaluru (erstwhile Dentsu Webchutney). Of the 47 metals coming home, the agency’s ‘Unfiltered History Tour’ campaign created for Vice Media has brought home 12 prominent awards across several categories, including three coveted Grand Prix, one Titanium and the biggest one of them all, the ‘Agency of the Year’.

CNBC-TV18 spoke with Amit Wadhwa and Ajay Gahlaut, the CEO and group CCO, at Dentsu Creative India to discuss the role of tech in these campaigns and understand what the awards wins means for the Indian ad industry.

According to Gahlaut, the time for technology in advertising has come but he also believes that it is the idea that resonates with people.

“Technology is just a tool, it is the idea that still makes it resonate with people. It is just that now we have these wonderful tech tools at our disposal, so ad agencies are catching up with the technology.”

Also, David Prager, Executive Vice President & Chief Brand Officer of De Beers spoke about key trends in the diamond jewellery market and the company’s plans for the Indian festive season.

Moreover, actor Shahid Kapoor and Varun Ganjoo, Co-Founder and Marketing Director of Baazi Games spoke about their new ad campaign which aims to create awareness about poker as a skill-based sport.

Watch the video for more.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Airbnb slumps as gloomy forecast fans slowdown fears
Airbnb slumps as gloomy forecast fans slowdown fears
May 9, 2024
(Reuters) - Airbnb ( ABNB ) shares tumbled more than 8% premarket on Thursday after weak forecasts for the second quarter stoked investor fears about slowing growth at the vacation rental firm and took the shine off a strong quarterly profit beat. The Easter holiday occurring in the first quarter rather than the second and currency-exchange impacts were partly to...
Viatris' Q1 Adjusted Earnings, Revenue Decrease; 2024 Outlook Reduced
Viatris' Q1 Adjusted Earnings, Revenue Decrease; 2024 Outlook Reduced
May 9, 2024
07:30 AM EDT, 05/09/2024 (MT Newswires) -- Viatris ( VTRS ) reported Q1 adjusted earnings Thursday of $0.67 per diluted share, down from $0.77 a year earlier. Analysts polled by Capital IQ expected $0.67. Total revenue for the quarter ended March 31 was $3.66 billion, compared with $3.73 billion a year earlier. Analysts surveyed by Capital IQ expected $3.69 billion....
Stevanato's Q1 Adjusted Earnings, Revenue Fall; 2024 Guidance Cut
Stevanato's Q1 Adjusted Earnings, Revenue Fall; 2024 Guidance Cut
May 9, 2024
07:34 AM EDT, 05/09/2024 (MT Newswires) -- Stevanato Group (STVN) reported Q1 adjusted earnings of 0.08 euros ($0.09) per diluted share, down from 0.11 a year earlier. Analysts polled by Capital IQ expected 0.11 euros. Revenue for the quarter ended March 31 was 236 million euros, down from 238 million euros a year earlier. Analysts surveyed by Capital IQ expected...
Merck's Late-Stage Study for Cancer Drug Keytruda Plus Chemotherapy Fails to Meet Primary Endpoint
Merck's Late-Stage Study for Cancer Drug Keytruda Plus Chemotherapy Fails to Meet Primary Endpoint
May 9, 2024
07:35 AM EDT, 05/09/2024 (MT Newswires) -- Merck ( MRK ) said Thursday that a late-stage trial assessing its cancer drug Keytruda plus chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of disease-free survival, or DFS, for the treatment of high-risk endometrial cancer post-surgery. Merck ( MRK ) said the trial's other primary endpoint...
Copyright 2023-2026 - www.financetom.com All Rights Reserved